226 related articles for article (PubMed ID: 34668223)
1. Fracture Risk Following an Atypical Femoral Fracture.
Bégin MJ; Audet MC; Chevalley T; Portela M; Padlina I; Hannouche D; Ing Lorenzini K; Meier R; Peter R; Uebelhart B; Rizzoli R; Ferrari S; Biver E
J Bone Miner Res; 2022 Jan; 37(1):87-94. PubMed ID: 34668223
[TBL] [Abstract][Full Text] [Related]
2. Bisphosphonates and the risk of atypical femur fractures.
Black DM; Condra K; Adams AL; Eastell R
Bone; 2022 Mar; 156():116297. PubMed ID: 34920168
[TBL] [Abstract][Full Text] [Related]
3. Clinical characteristics, densitometric parameters and outcomes of patients with atypical femoral fractures related to bisphosphonate treatment for osteoporosis.
Wong CH; Kan AKC; Tsoi KH; Chan SSY; Jiang NS; Loong CHN; Fong CHY; Wong JSH; Shea GKH; Cheung CL; Lee CH; Tan KCB; Woo YC; Lui DTW
Endocrine; 2024 Apr; 84(1):223-235. PubMed ID: 37985574
[TBL] [Abstract][Full Text] [Related]
4. Trends in the incidence of atypical femoral fractures and bisphosphonate therapy.
Clout A; Narayanasamy N; Harris I
J Orthop Surg (Hong Kong); 2016 Apr; 24(1):36-40. PubMed ID: 27122510
[TBL] [Abstract][Full Text] [Related]
5. Incidence and medical management of bisphosphonate-associated atypical femoral fractures in a major trauma centre: a retrospective observational study.
Eisenstein N; Kasavkar G; Bhavsar D; Khan FS; Paskins Z
BMC Musculoskelet Disord; 2017 Jan; 18(1):29. PubMed ID: 28114975
[TBL] [Abstract][Full Text] [Related]
6. Characteristics of bisphosphonate and non-bisphosphonate related atypical femoral fracture in a South East Asian population - Secondary analysis.
Gani LU; Anthony NF; Dacay LM; Tan PT; Chong LR; King TFJ
Bone; 2022 Sep; 162():116455. PubMed ID: 35688361
[TBL] [Abstract][Full Text] [Related]
7. Risk of complete atypical femur fracture with Oral bisphosphonate exposure beyond three years.
Lo JC; Neugebauer RS; Ettinger B; Chandra M; Hui RL; Ott SM; Grimsrud CD; Izano MA
BMC Musculoskelet Disord; 2020 Dec; 21(1):801. PubMed ID: 33272248
[TBL] [Abstract][Full Text] [Related]
8. Bisphosphonate treatment and the risk of atypical femoral fracture among patients participating in a Fracture Liaison Service of a tertiary medical center.
Bareli N; Gat R; Makarov V; Siris E; Fraenkel M; Yoel U
Arch Osteoporos; 2021 Jun; 16(1):86. PubMed ID: 34089098
[TBL] [Abstract][Full Text] [Related]
9. Different surgical outcomes in a patient with bilateral atypical femoral fracture related to bisphosphonate use with or without teriparatide treatment.
Zhang HY; Weng HL; Li M; Zhang J
Osteoporos Int; 2019 Nov; 30(11):2349-2354. PubMed ID: 31428823
[TBL] [Abstract][Full Text] [Related]
10. Medical Management of Patients After Atypical Femur Fractures: a Systematic Review and Recommendations From the European Calcified Tissue Society.
van de Laarschot DM; McKenna MJ; Abrahamsen B; Langdahl B; Cohen-Solal M; Guañabens N; Eastell R; Ralston SH; Zillikens MC
J Clin Endocrinol Metab; 2020 May; 105(5):1682-99. PubMed ID: 31867670
[TBL] [Abstract][Full Text] [Related]
11. Incidence, risk factors, and fracture healing of atypical femoral fractures: a multicenter case-control study.
Lim SJ; Yeo I; Yoon PW; Yoo JJ; Rhyu KH; Han SB; Lee WS; Song JH; Min BW; Park YS
Osteoporos Int; 2018 Nov; 29(11):2427-2435. PubMed ID: 30039251
[TBL] [Abstract][Full Text] [Related]
12. Radiological criteria for atypical features of femur fractures: what we can learn when applied in a clinical study setting.
LeBlanc ES; Rosales AG; Genant HK; Dell RM; Friess DM; Boardman DL; Santora AC; Bauer DC; de Papp AE; Black DM; Orwoll ES
Osteoporos Int; 2019 Jun; 30(6):1287-1295. PubMed ID: 30809724
[TBL] [Abstract][Full Text] [Related]
13. Atypical Femoral Fracture in Rheumatoid Arthritis Patients Treated With Bisphosphonates: A Nested Case-Control Study.
Koh JH; Myong JP; Jung SM; Lee J; Kwok SK; Park SH; Ju JH
Arthritis Rheumatol; 2016 Jan; 68(1):77-82. PubMed ID: 26360133
[TBL] [Abstract][Full Text] [Related]
14. Potential bone fragility of mid-shaft atypical femoral fracture: Biomechanical analysis by a CT-based nonlinear finite element method.
Tano A; Oh Y; Fukushima K; Kurosa Y; Wakabayashi Y; Fujita K; Yoshii T; Okawa A
Injury; 2019 Nov; 50(11):1876-1882. PubMed ID: 31519437
[TBL] [Abstract][Full Text] [Related]
15. Healing of bisphosphonate-associated atypical femoral fractures in patients with osteoporosis: a comparison between treatment with and without teriparatide.
Miyakoshi N; Aizawa T; Sasaki S; Ando S; Maekawa S; Aonuma H; Tsuchie H; Sasaki H; Kasukawa Y; Shimada Y
J Bone Miner Metab; 2015 Sep; 33(5):553-9. PubMed ID: 25227287
[TBL] [Abstract][Full Text] [Related]
16. Bisphosphonate therapy associated with bilateral atypical femoral fracture and delayed union.
Gárgyán I; Dózsai D; Csonka I; Rárosi F; Bodzay T; Csonka Á
Jt Dis Relat Surg; 2022; 33(1):24-32. PubMed ID: 35361077
[TBL] [Abstract][Full Text] [Related]
17. MANAGEMENT OF ENDOCRINE DISEASE: Atypical femoral fractures: risks and benefits of long-term treatment of osteoporosis with anti-resorptive therapy.
Adler RA
Eur J Endocrinol; 2018 Mar; 178(3):R81-R87. PubMed ID: 29339529
[TBL] [Abstract][Full Text] [Related]
18. Differences in bone histomorphometry between White postmenopausal women with and without atypical femoral fracture after long-term bisphosphonate therapy.
Qiu S; Dhaliwal R; Divine G; Warner E; Rao SD
J Bone Miner Res; 2024 May; 39(4):417-424. PubMed ID: 38477744
[TBL] [Abstract][Full Text] [Related]
19. The effects of teriparatide on acceleration of bone healing following atypical femoral fracture: comparison between daily and weekly administration.
Tsuchie H; Miyakoshi N; Iba K; Kasukawa Y; Nozaka K; Dohke T; Kosukegawa I; Aizawa T; Maekawa S; Abe H; Takeshima M; Tomite T; Segawa T; Ouchi K; Kinoshita H; Suzuki M; Yamashita T; Shimada Y
Osteoporos Int; 2018 Dec; 29(12):2659-2665. PubMed ID: 30105400
[TBL] [Abstract][Full Text] [Related]
20. High bisphosphonate treatment rates and the prevalence of atypical femoral fractures in patients with systematic lupus erythematosus: a single-center retrospective study performed in Japan.
Sato H; Kondo N; Wakamatsu A; Kobayashi D; Nakatsue T; Wada Y; Kuroda T; Suzuki Y; Nakano M; Endo N; Narita I
Rheumatol Int; 2019 Oct; 39(10):1803-1810. PubMed ID: 31385078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
